Location Cambridge, Massachusetts, United States Regions Greater Boston Area, East Coast, New England Gender Male
LinkedIn View on LinkedIn
Dr. Gordon Wong is an accomplished executive and scientist with a successful record of innovative leadership and management in corporate venture, biologics technology, discovery and development.
At Biogen Idec, Dr. Wong, VP led efforts to find and develop strategic technologies and products. His successes have led to the licensing of biologics
from Amorfix (2010) and Avitx (2009), the acquisition of Syntonix (2007) and to the founding of Virdante (2008).
Prior to Biogen, Dr. Wong was co-Founder and CSO of Compound Therapeutics ( renamed Adnexus) which was acquired for $475 M USD by Bristol Meyers Squibb. Dr. Wong has an accomplished record of inventions and publications in molecular biology, gene discovery, functional genomics, protein engineering and drug discovery.
He has discovered 7 proprietary biologics drug candidates (GM CSF, M CSF, IL-6, LIF, IL-12, JE cytokine, EPO receptor) of which 4 entered Phase I /II clinical trials. Dr. Wong has been awarded 30 issued US patents, 18 pending US patent applications and over 75 publications. He has invented novel molecular biology (Expression cDNA cloning), protein engineering (AdZyme) and genomics technologies (Gene Expression Monitoring and DNA tagging chemistries) and led clinical development programs.
